Boundless Bio Management
Management criteria checks 1/4
Boundless Bio's CEO is Zach Hornby, appointed in May 2019, has a tenure of 5.67 years. total yearly compensation is $2.37M, comprised of 20.9% salary and 79.1% bonuses, including company stock and options. directly owns 1.15% of the company’s shares, worth $687.18K. The average tenure of the management team and the board of directors is 3 years and 3 years respectively.
Key information
Zach Hornby
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 20.9% |
| CEO tenure | 5.7yrs |
| CEO ownership | 1.1% |
| Management average tenure | 3yrs |
| Board average tenure | 3yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$58m |
| Mar 31 2024 | n/a | n/a | -US$53m |
| Dec 31 2023 | US$2m | US$495k | -US$49m |
| Sep 30 2023 | n/a | n/a | -US$49m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$47m |
| Dec 31 2022 | US$693k | US$476k | -US$46m |
Compensation vs Market: Zach's total compensation ($USD2.37M) is above average for companies of similar size in the US market ($USD645.47K).
Compensation vs Earnings: Zach's compensation has increased whilst the company is unprofitable.
CEO
Zach Hornby (45 yo)
5.7yrs
Tenure
US$2,372,863
Compensation
Mr. Zachary Hornby, also known as Zach, serves as Director at Radionetics Oncology, Inc. since October 2021. He serves as Director at Novome Biotechnologies, Inc. since May 2021. He is also a member of the...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 6.1yrs | US$61.17k | 0.46% $ 274.9k | |
| CEO, President & Director | 5.7yrs | US$2.37m | 1.15% $ 687.2k | |
| Chief Scientific Officer | 5.2yrs | US$903.51k | 0.11% $ 68.7k | |
| Chief Medical Officer | 2.9yrs | US$996.66k | 0% $ 0 | |
| Senior VP of Finance & Controller | 3.6yrs | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 3.4yrs | no data | no data | |
| Chief Business Officer | 3.4yrs | no data | no data | |
| Senior Vice President of Drug Discovery | 3yrs | no data | no data | |
| Senior Vice President of Talent & Culture | 3yrs | no data | no data | |
| Senior Vice President of Precision Medicine | less than a year | no data | no data | |
| Senior Vice President of Program Team | less than a year | no data | no data | |
| Senior Vice President of Clinical Operations | less than a year | no data | no data |
3.0yrs
Average Tenure
51.5yo
Average Age
Experienced Management: BOLD's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 6.1yrs | US$61.17k | 0.46% $ 274.9k | |
| CEO, President & Director | 5.7yrs | US$2.37m | 1.15% $ 687.2k | |
| Member of Clinical Advisory Board | 1.3yrs | no data | no data | |
| Independent Director | 5.6yrs | no data | 0.026% $ 15.7k | |
| Scientific & Clinical Advisor | no data | US$92.28k | no data | |
| Independent Director | 3yrs | US$66.55k | 0% $ 0 | |
| Independent Director | 2.9yrs | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.3yrs | US$102.74k | 0% $ 0 | |
| Scientific & Clinical Advisor | no data | no data | no data | |
| Independent Director | 1.3yrs | US$102.74k | 0% $ 0 | |
| Scientific & Clinical Advisor | no data | no data | no data |
3.0yrs
Average Tenure
52yo
Average Age
Experienced Board: BOLD's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 01:58 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Boundless Bio, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chris Shibutani | Goldman Sachs |
| Michael Schmidt | Guggenheim Securities, LLC |
| Andrew Berens | Leerink Partners LLC |